These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21890624)

  • 21. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
    Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
    Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
    Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A
    Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
    Fink J; Sanders K; Rippl A; Finkernagel S; Beckers TL; Schmidt M
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3189-97. PubMed ID: 18089713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway.
    Ma X; Wang L; Huang D; Li Y; Yang D; Li T; Li F; Sun L; Wei H; He K; Yu F; Zhao D; Hu L; Xing S; Liu Z; Li K; Guo J; Yang Z; Pan X; Li A; Shi Y; Wang J; Gao P; Zhang H
    Nat Commun; 2017 Nov; 8(1):1506. PubMed ID: 29138396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
    Shtivelman E
    Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
    Peng Y; Liu Y; Gao Y; Yuan B; Qi X; Fu Y; Zhu Q; Cao T; Zhang S; Yin L; Li X
    J Exp Clin Cancer Res; 2019 Nov; 38(1):468. PubMed ID: 31730000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purification and proteomic identification of putative upstream regulators of polo-like kinase-1 from mitotic cell extracts.
    Ji JH; Hwang HI; Lee HJ; Hyun SY; Kang HJ; Jang YJ
    FEBS Lett; 2010 Oct; 584(20):4299-305. PubMed ID: 20869364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
    Zhang Z; Chen L; Wang H; Ahmad N; Liu X
    Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells.
    Schmidt M; Hofmann HP; Sanders K; Sczakiel G; Beckers TL; Gekeler V
    Mol Cancer Ther; 2006 Apr; 5(4):809-17. PubMed ID: 16648550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade.
    Li R; Chen DF; Zhou R; Jia SN; Yang JS; Clegg JS; Yang WJ
    J Biol Chem; 2012 May; 287(19):15923-34. PubMed ID: 22427657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polo-like kinase 1 inhibits DNA damage response during mitosis.
    Benada J; Burdová K; Lidak T; von Morgen P; Macurek L
    Cell Cycle; 2015; 14(2):219-31. PubMed ID: 25607646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells.
    Luo ML; Li J; Shen L; Chu J; Guo Q; Liang G; Wu W; Chen J; Chen R; Song E
    J Natl Cancer Inst; 2020 Apr; 112(4):356-368. PubMed ID: 31286138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
    Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
    Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress.
    Bassi C; Ho J; Srikumar T; Dowling RJ; Gorrini C; Miller SJ; Mak TW; Neel BG; Raught B; Stambolic V
    Science; 2013 Jul; 341(6144):395-9. PubMed ID: 23888040
    [TBL] [Abstract][Full Text] [Related]  

  • 40.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.